SCIENTIFIC LITERATURE · MED

Discovery of VU2957 (Valiglurax): An mGlu<sub>4</sub> Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.

Panarese JD, Engers DW, Wu YJ, Bronson JJ, Macor JE, Chun A, Rodriguez AL, Felts AS, Engers JL, Loch MT, Emmitte KA, Castelhano AL, Kates MJ, Nader MA, Jones CK, Blobaum AL, Conn PJ, Niswender CM, Hopkins CR, Lindsley CW.

ACS Med Chem Lett · 2018-10-16

DOI: 10.1021/acsmedchemlett.8b00426PMID: 30891122

Check source for accessrapid-communication; Journal ArticleOriginal source ↗

Research overview

Source publication and reading guides

This section identifies the original publication. Follow the source for its authors and journal.

Read the original publication ↗

Scientific assessment

Research question

Assess the question within the original study’s scope.

Methods & sample

Check the source article for study design and sample details.

Key findings

An editorially approved findings summary is not yet published for this record.

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.